Release Summary

Vertex Announces German Reimbursement Agreement for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12+ with Two Copies of F508del

Vertex Pharmaceuticals Incorporated